Asset
Celecoxib
NeuroSense Therapeutics Ltd. Ordinary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05436678 | phase1 | completed | 2022-07-26 | 2022-08-19 | NeuroSense Therapeutics Ltd. | A Multiple-Dose PK Study to Evaluate the Comparative Bioavailability of PrimeC Tablets to Ciprofloxacin Tablets Co-administered With Celecoxib Capsules, in Healthy Adult Subject |
| NCT05232461 | phase1 | completed | 2022-04-08 | 2022-04-21 | NeuroSense Therapeutics Ltd. | A Pilot Study to Evaluate the PK Profile of PrimeC-ER Tablets in Healthy Adult Subjects |
| NCT04090684 | phase1 | completed | 2019-12-09 | 2021-09-27 | NeuroSense Therapeutics Ltd. | Ciprofloxacin/Celecoxib Combination in Patients With ALS |
| NCT04165850 | phase2 | completed | 2019-11-25 | 2021-01-19 | NeuroSense Therapeutics Ltd. | Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS |
FDA applications (0)
This company has no applications containing this asset.